|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI
|
|
2
|
de Kort S, Masclee AAM, Sanduleanu S,
Weijenberg MP, van Herk-Sukel MPP, Oldenhof NJJ, van den Bergh JPW,
Haak HR and Janssen-Heijnen ML: Higher risk of colorectal cancer in
patients with newly diagnosed diabetes mellitus before the age of
colorectal cancer screening initiation. Sci Rep. 7:465272017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun L and Yu S: Diabetes mellitus is an
independent risk factor for colorectal cancer. Dig Dis Sci.
57:1586–1597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van de Poll-Franse LV, Haak HR, Coebergh
JW, Janssen-Heijnen ML and Lemmens VE: Disease-specific mortality
among stage I–III colorectal cancer patients with diabetes: A large
population-based analysis. Diabetologia. 55:2163–2172. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Yee D: Diabetes and cancer: A consensus report. Diabetes Care.
33:1674–1685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mills KT, Bellows CF, Hoffman AE, Kelly TN
and Gagliardi G: Diabetes mellitus and colorectal cancer prognosis:
A meta-analysis. Dis Colon Rectum. 56:1304–1319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharma A, Ng H, Kumar A, Teli K, Randhawa
J, Record J and Maroules M: Colorectal cancer: Histopathologic
differences in tumor characteristics between patients with and
without diabetes. Clin Colorectal Cancer. 13:54–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang J, Nishihara R, Zhang X, Ogino S and
Qian ZR: Energy sensing pathways: Bridging type 2 diabetes and
colorectal cancer? J Diabetes Complications. 31:1228–1236. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ariyasu D, Yoshida H and Hasegawa Y:
Endoplasmic Reticulum (ER) stress and endocrine disorders. Int J
Mol Sci. 18:2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dumartin L, Alrawashdeh W, Trabulo SM,
Radon TP, Steiger K, Feakins RM, di Magliano MP, Heeschen C,
Esposito I, Lemoine NR and Crnogorac-Jurcevic T: ER stress protein
AGR2 precedes and is involved in the regulation of pancreatic
cancer initiation. Oncogene. 36:3094–3103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brychtova V, Vojtesek B and Hrstka R:
Anterior gradient 2: A novel player in tumor cell biology. Cancer
Lett. 304:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tian S, Hu J, Tao K, Wang J, Chu Y, Li J,
Liu Z, Ding X, Xu L, Li Q, et al: Secreted AGR2 promotes invasion
of colorectal cancer cells via Wnt11-mediated non-canonical Wnt
signaling. Exp Cell Res. 364:198–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Higa A, Mulot A, Delom F, Bouchecareilh M,
Nguyên DT, Boismenu D, Wise MJ and Chevet E: Role of pro-oncogenic
protein disulfide isomerase (PDI) family member anterior gradient 2
(AGR2) in the control of endoplasmic reticulum homeostasis. J Biol
Chem. 286:44855–44868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chevet E, Fessart D, Delom F, Mulot A,
Vojtesek B, Hrstka R, Murray E, Gray T and Hupp T: Emerging roles
for the pro-oncogenic anterior gradient-2 in cancer development.
Oncogene. 32:2499–2509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inzucchi SE, Bergenstal RM, Buse JB,
Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R and
Matthews DR; American Diabetes Association (ADA); European
Association for the Study of Diabetes (EASD), : Management of
hyperglycemia in type 2 diabetes: A patient-centered approach:
Position statement of the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD). Diabetes
Care. 35:1364–1379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Higurashi T and Nakajima A: Metformin and
colorectal cancer. Front Endocrinol. 9:6222018. View Article : Google Scholar
|
|
17
|
Meng F, Song L and Wang W: Metformin
improves overall survival of colorectal cancer patients with
diabetes: A meta-analysis. J Diabetes Res. 2017:50632392017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mogavero A, Maiorana MV, Zanutto S,
Varinelli L, Bozzi F, Belfiore A, Volpi CC, Gloghini A, Pierotti MA
and Gariboldi M: Metformin transiently inhibits colorectal cancer
cell proliferation as a result of either AMPK activation or
increased ROS production. Sci Rep. 7:159922017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Diaz-Morales N, Iannantuoni F,
Escribano-Lopez I, Bañuls C, Rovira-Llopis S, Sola E, Rocha M,
Hernandez-Mijares A and Victor VM: Does metformin modulate
endoplasmic reticulum stress and autophagy in type 2 diabetic
peripheral blood mononuclear cells? Antioxid Redox Signal.
28:1562–1569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kobiela J, Dobrzycka M, Jędrusik P,
Kobiela P, Spychalski P, Śledziński Z and Zdrojewski T: Metformin
and colorectal cancer-a systematic review. Exp Clin Endocrinol
Diabetes. 127:445–454. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yue W, Wang T, Zachariah E, Lin Y, Yang
CS, Xu Q, DiPaola RS and Tan XL: Transcriptomic analysis of
pancreatic cancer cells in response to metformin and aspirin: An
implication of synergy. Sci Rep. 5:133902015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arumugam T, Deng D, Bover L, Wang H,
Logsdon CD and Ramachandran V: New blocking antibodies against
novel AGR2-C4.4A pathway reduce growth and metastasis of pancreatic
tumors and increase survival in mice. Mol Cancer Ther. 14:941–951.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hrstka R, Bouchalova P, Michalova E,
Matoulkova E, Muller P, Coates PJ and Vojtesek B: AGR2 oncoprotein
inhibits p38 MAPK and p53 activation through a DUSP10-mediated
regulatory pathway. Mol Oncol. 10:652–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hrstka R, Brychtova V, Fabian P, Vojtesek
B and Svoboda M: AGR2 predicts tamoxifen resistance in
postmenopausal breast cancer patients. Dis Markers. 35:207–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung
HW, Boehm JS, Ni M, Geisen C, Root DE, et al: Control of cyclin D1
and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer
Cell. 16:413–424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hrstka R, Nenutil R, Fourtouna A, Maslon
MM, Naughton C, Langdon S, Murray E, Larionov A, Petrakova K,
Muller P, et al: The pro-metastatic protein anterior gradient-2
predicts poor prognosis in tamoxifen-treated breast cancers.
Oncogene. 29:4838–4847. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ostatná V, Vargová V, Hrstka R, Ďurech M,
Vojtěšek B and Paleček E: Effect of His6-tagging of
anterior gradient 2 protein on its electro-oxidation. Electrochim
Acta. 150:218–222. 2014. View Article : Google Scholar
|
|
28
|
Ma SR, Mao L, Deng WW, Li YC, Bu LL, Yu
GT, Zhang WF and Sun ZJ: AGR2 promotes the proliferation, migration
and regulates epithelial-mesenchymal transition in salivary adenoid
cystic carcinoma. Am J Transl Res. 9:507–519. 2017.PubMed/NCBI
|
|
29
|
Park K, Chung YJ, So H, Kim K, Park J, Oh
M, Jo M, Choi K, Lee EJ, Choi YL, et al: AGR2, a mucinous ovarian
cancer marker, promotes cell proliferation and migration. Exp Mol
Med. 43:91–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim J, Yang G, Kim Y, Kim J and Ha J: AMPK
activators: Mechanisms of action and physiological activities. Exp
Mol Med. 48:e2242016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Andrzejewski S, Gravel SP, Pollak M and
St-Pierre J: Metformin directly acts on mitochondria to alter
cellular bioenergetics. Cancer Metab. 2:122014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J 348 Pt. 3:607–614. 2000. View Article : Google Scholar
|
|
35
|
Larsson SC, Orsini N and Wolk A: Diabetes
mellitus and risk of colorectal cancer: A meta-analysis. J Natl
Cancer Inst. 97:1679–1687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zanders MM, Vissers PA, Haak HR and van de
Poll-Franse LV: Colorectal cancer, diabetes and survival:
Epidemiological insights. Diabetes Metab. 40:120–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim JH, Lee KJ, Seo Y, Kwon JH, Yoon JP,
Kang JY, Lee HJ, Park SJ, Hong SP, Cheon JH, et al: Effects of
metformin on colorectal cancer stem cells depend on alterations in
glutamine metabolism. Sci Rep. 8:4092018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nangia-Makker P, Yu Y, Vasudevan A,
Farhana L, Rajendra SG, Levi E and Majumdar AP: Metformin: A
potential therapeutic agent for recurrent colon cancer. PLoS One.
9:e843692014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herzig S and Shaw RJ: AMPK: Guardian of
metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol.
19:121–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Emami Riedmaier A, Fisel P, Nies AT,
Schaeffeler E and Schwab M: Metformin and cancer: From the old
medicine cabinet to pharmacological pitfalls and prospects. Trends
Pharmacol Sci. 34:126–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hrstka R, Murray E, Brychtova V, Fabian P,
Hupp TR and Vojtesek B: Identification of an AKT-dependent
signalling pathway that mediates tamoxifen-dependent induction of
the pro-metastatic protein anterior gradient-2. Cancer Lett.
333:187–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li Z, Wu Z, Chen H, Zhu Q, Gao G, Hu L,
Negi H, Kamle S and Li D: Induction of anterior gradient 2 (AGR2)
plays a key role in insulin-like growth factor-1 (IGF-1)-induced
breast cancer cell proliferation and migration. Med Oncol.
32:5772015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matoulkova E, Sommerova L, Pastorek M,
Vojtesek B and Hrstka R: Regulation of AGR2 expression via 3′UTR
shortening. Exp Cell Res. 356:40–47. 2017.PubMed/NCBI
|
|
44
|
Pandurangan AK: Potential targets for
prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt
pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tian SB, Tao KX, Hu J, Liu ZB, Ding XL,
Chu YN, Cui JY, Shuai XM, Gao JB, Cai KL, et al: The prognostic
value of AGR2 expression in solid tumours: A systematic review and
meta-analysis. Sci Rep. 7:155002017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alves MR, E Melo NC, Barros-Filho MC, do
Amaral NS, Silva FIB, Baiocchi Neto G, Soares FA, de Brot Andrade L
and Rocha RM: Downregulation of AGR2, p21, and cyclin D and
alterations in p53 function were associated with tumor progression
and chemotherapy resistance in epithelial ovarian carcinoma. Cancer
Med. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Riener MO, Thiesler T, Hellerbrand C,
Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W,
Terracciano L and Kristiansen G: Loss of anterior gradient-2
expression is an independent prognostic factor in colorectal
carcinomas. Eur J Cancer. 50:1722–1730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen N and Karantza-Wadsworth V: Role and
regulation of autophagy in cancer. Biochim Biophys Acta.
1793:1516–1523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Madia F, Grossi V, Peserico A and Simone
C: Updates from the intestinal front line: Autophagic weapons
against inflammation and cancer. Cells. 1:535–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang HZ, Ma Y, Zhou Y, Xu LM, Chen XJ,
Ding WB and Zou HB: Autophagy contributes to the enrichment and
survival of colorectal cancer stem cells under oxaliplatin
treatment. Cancer Lett. 361:128–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li J, Hou N, Faried A, Tsutsumi S and
Kuwano H: Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur
J Cancer. 46:1900–1909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Abdelsatir AA, Husain NE, Hassan AT,
Elmadhoun WM, Almobarak AO and Ahmed MH: Potential benefit of
metformin as treatment for colon cancer: The evidence so far. Asian
Pac J Cancer Prev. 16:8053–8058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hur KY and Lee MS: New mechanisms of
metformin action: Focusing on mitochondria and the gut. J Diabetes
Investig. 6:600–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang L, Wang X and Wang CC: Protein
disulfide-isomerase, a folding catalyst and a redox-regulated
chaperone. Free Radic Biol Med. 83:305–313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Schexnayder C, Broussard K, Onuaguluchi D,
Poché A, Ismail M, McAtee L, Llopis S, Keizerweerd A, McFerrin H
and Williams C: Metformin inhibits migration and invasion by
suppressing ROS production and COX2 expression in MDA-MB-231 breast
cancer cells. Int J Mol Sci. 19:2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Queiroz EA, Puukila S, Eichler R, Sampaio
SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB and
Khaper N: Metformin induces apoptosis and cell cycle arrest
mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast
cancer cells. PLoS One. 9:e982072014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ramachandran V, Arumugam T, Wang H and
Logsdon CD: Anterior gradient 2 is expressed and secreted during
the development of pancreatic cancer and promotes cancer cell
survival. Cancer Res. 68:7811–7818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tiemann K, Garri C, Lee SB, Malihi PD,
Park M, Alvarez RM, Yap LP, Mallick P, Katz JE, Gross ME and Kani
K: Loss of ER retention motif of AGR2 can impact mTORC signaling
and promote cancer metastasis. Oncogene. 38:3003–3018. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Maurel M, Obacz J, Avril T, Ding YP,
Papadodima O, Treton X, Daniel F, Pilalis E, Hörberg J, Hou W, et
al: Control of anterior GRadient 2 (AGR2) dimerization links
endoplasmic reticulum proteostasis to inflammation. EMBO Mol Med.
11:2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Miranda VC, Braghiroli MI, Faria LD,
Bariani G, Alex A, Bezerra Neto JE, Capareli FC, Sabbaga J, Lobo
Dos Santos JF, Hoff PM and Riechelmann RP: Phase 2 trial of
metformin combined with 5-Fluorouracil in patients with refractory
metastatic colorectal cancer. Clin Colorectal Cancer.
15:321.e1–328.e1. 2016. View Article : Google Scholar
|
|
62
|
Richard SM and Martinez Marignac VL:
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by
metformin and ribavirin and differences in response to
mitochondrial glutaminase inhibition. J Cancer Res Ther.
11:336–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
